What to consider before investing in small-cap indexes
Small-cap index trackers show why your choice of benchmark can make a large difference to long-term returns


The small-cap effect is more inconsistent than many investors assume. Smaller stocks have beaten larger ones over decades, but they have oscillated between long spells of outperformance and underperformance.
In recent years, they have seen a long streak of underperformance. That doesn’t mean that we should ignore small caps, but we should think about whether this is likely to persist and why.
However, before getting that far, investors who want to track small-cap indexes need to consider what they are buying. We can see this most clearly in the US, where there is a choice of competing small-cap indexes.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Look beyond the obvious in US small-cap indexes
The best-known US small-cap index – and the one with the most assets in UK-listed exchange traded funds (ETFs) – is the Russell 2000. This covers the 2,000 smallest stocks in the Russell 3000, which is FTSE Russell’s whole-of-market US benchmark. As this implies, there is a Russell 1000 index of larger stocks, which gets little attention – all the focus at the larger end of the market is on the S&P 500 index. In turn, the S&P 500 is one of three benchmarks in its own series, alongside the S&P MidCap 400 and the S&P SmallCap 600, which are often ignored in favour of the Russell 2000.
Add all these numbers up and you can quickly see that while both the S&P 600 and Russell 2000 are viewed as small-cap proxies, they will have different market coverage. There is overlap, but some stocks will be in one and not the other.
Still, the most critical difference between the two is something less obvious. S&P requires a stock to have been profitable for four quarters before being added to the index (although not to stay in it), while FTSE Russell has no such requirement. This acts as a very crude quality filter. Some passive purists object to this – they argue an index should simply reflect the market – but the S&P 600 has beaten the Russell 2000 by around 1%-2% per year over longer time periods (although obviously not in every individual year – the Russell did a bit better in 2023).
Appeal of UK small cap indexes
We don’t have quite the same choice for the UK, where the options are mostly limited to FTSE 250 funds. There are indexes such as the FTSE SmallCap and the FTSE Fledging, as well as the FTSE Aim series (the latter is not simply about size – some Aim stocks are FTSE 250-sized, but don’t comply with the rules for a full listing and so aren’t included in the main indexes). However, trackers aren’t available for any of these.
There is one exception: the MSCI UK Small Cap, where iShares offers an ETF. In one way, this is less focused on small stocks than the FTSE 250, since it includes the bottom end of the FTSE 100, but there are other differences. It doesn’t include investment trusts – about 30% of the FTSE 250 – but it does include some of the larger Aim stocks. How much does this matter? For a long time, not much – but recently, a large gap has opened up.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
-
How Corpay is cashing in on expenses
Financial technology company Corpay has found a profitable niche managing corporate payments
By Dr Matthew Partridge Published
-
Are UK Reits the most unloved asset?
Recent updates from UK Reits are looking more positive, but the market remains entirely unimpressed
By Cris Sholto Heaton Published
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fades
Food-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
By Dr Matthew Partridge Published